Introduction {#Sec1}
============

Breast cancer is the most commonly diagnosed cancer in women and the second leading cause of cancer-related death in women \[[@CR1]\]. Breast cancer is a diverse disease with different histological tumor subtypes that can be further characterized on the basis of specific markers. The most commonly examined immunohistochemical markers are estrogen receptor (ER), progesterone receptor (PgR), and human epidermal group factor receptor 2 (HER2) \[[@CR2]\]. HER2 is a tyrosine kinase member of the epidermal growth factor receptor (EGFR) family and HER2 gene is located on the long arm of chromosome 17 (17q12--21.32). HER2 protein is activated upon receptor dimerization that causes autophosphorylation and subsequent downstream signaling \[[@CR3], [@CR4]\]. Patients with HER2 positive disease typically have a worse prognosis with characteristics of aggressive tumor progress and shorter patient survival.

HER2 positive status of breast cancer patients is assessed by the HER2 protein overexpression or HER2 gene amplification. HER2 protein expression is examined using bright filed HER2 immunohistochemistry (IHC) with 3,3′-diaminobenzidine (DAB) detection and HER2 gene level is evaluated by HER2 in situ hybridization (ISH) methods, utilizing various detection approaches such as dual color fluorescent ISH (FISH), chromogenic ISH (CISH), silver ISH (SISH), and dual color ISH (DISH) \[[@CR5], [@CR6]\]. Recently, the gene-protein assay (GPA) has been introduced as a new method for simultaneous evaluation of U.S. Food and Drug Administration (FDA)-approved HER2 IHC and HER2 DISH assays in a single tissue section, allowing pathologists to examine both HER2 protein and HER2 gene statuses simultaneously at the single cell level \[[@CR7]\]. HER2 intratumoral heterogeneity in breast cancer can be detected effectively by the concurrent observations of HER2 IHC and DISH results in breast cancer \[[@CR7]\].

Trastuzumab, a humanized monoclonal antibody to HER2 protein, binds to the extracellular domain of HER2 in the cell membrane of carcinoma cells for the suppressions of HER2 signaling and the inhibition of cell proliferation by arresting the cell cycle during the G1 phase \[[@CR8], [@CR9]\]. In addition, antibody binding to the HER2 extracellular domain leads to antibody-dependent cell-mediated cytotoxicity (ADCC) triggering the carcinoma cell death by immune cells \[[@CR10], [@CR11]\]. The strategy of breast cancer treatment changed drastically after trastuzumab was accepted by FDA in 1998 for the treatment of HER2 overexpressing breast cancer. Moreover, additional HER2-targeted therapy agents such as lapatinib \[[@CR12]\], pertuzumab \[[@CR13]\], and ado-trastuzumab emtansine, known as T-DM1 \[[@CR14]\], have been approved for the treatment of HER2 overexpressing breast cancers. On the other hand, National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 that compared a standard chemotherapy and a trastuzumab adjuvant therapy with chemotherapy suggested some HER2 negative patients may benefit moderately from adjuvant trastuzumab therapy \[[@CR15], [@CR16]\]. A randomized phase III trial of adjuvant trastuzumab therapy (NSABP B-47) with 3260 patients who are HER2 IHC 1+ or 2+ scores, but HER2 FISH negative will reveal how the HER2 targeted therapy is effective to treat HER2 negative breast cancer patients \[[@CR17]\].

HER2 tumor heterogeneity is a major challenge for accurate evaluation of HER2 status in breast cancer and the heterogeneity can result in discordant between HER2 IHC and ISH assays \[[@CR18]\]. The HER2 tumor heterogeneity might affect the management of early and advanced breast cancer patients \[[@CR19]\]. However, theories of HER2 tumor heterogeneity evaluations are mainly based on expert opinions, but not based on clinical outcome of breast cancer patients. Though, recent studies reported that breast cancer patients with the HER2 intratumoral heterogeneity had reduced disease-free survival in HER2 positive invasive breast cancers \[[@CR20]\] and influenced the effectiveness of trastuzumab therapy in metastatic HER2 positive breast cancer \[[@CR21]\]. HER2 tumor heterogeneity is more often observed with HER2 IHC 2+/equivocal cases, mainly in HER2 gene negative status assessed cases containing individual amplified HER2 gene tumor cells \[[@CR22]\]. Furthermore, breast cancer with HER2 heterogeneity presented an aggressive phenotype \[[@CR23]\]. However, the significance of HER2 heterogeneity evaluation has not been established for a long-term breast cancer patient outcome after the surgical procedure yet. In the current study, we investigated the relationship between HER2 gene and protein status of invasive breast cancer cases using the HER2 GPA method and analyzed the correlation between the presence of HER2 heterogeneity and the prognosis of these breast cancer patients after surgery.

Methods {#Sec2}
=======

Patient backgrounds and eligibility {#Sec3}
-----------------------------------

Two hundred eighty (280) consecutive breast cancer patients with invasive lesions larger than 5 mm diagnosed at Saitama Cancer Center from January 2000 to December 2001 were evaluated in this study. However, male and bilateral breast cancer patients were excluded. All patients underwent breast-conserving surgery or modified radical mastectomy. Clinicopathological parameters including tumor size and nodal status were retrieved from medical reports and follow-up data were obtained from the database of the breast cancer clinic division. Because adjuvant administration had not been approved in Japan before 2008, no HER2 positive patient received adjuvant trastuzumab therapy. However, 76 % of HER2 positive breast cancer patients who presented with the distant metastasis during a follow-up duration received trastuzumab therapy combined with chemotherapy.

This study was conducted in accordance with the Declaration of Helsinki and the study protocol was approved by the Institutional Review Board of Saitama Cancer Center. All patients included in this study provided written informed consents for a comprehensive scientific examination of clinical samples. This retrospective translational study was performed as a collaborative research project between Saitama Prefectural Government, Japan and Ventana Medical Systems, Inc., the United States after execution of a formal contract. In order to keep the integrity of results and analyses of the current study, study activities were performed separately by three groups: (1) the pathological examination group; (2) the GPA examination group; and (3) the clinical analysis group. No clinical information was provided to the GPA analysis group and the GPA analysis data were completely closed before data were transferred to the clinical analysis group.

Histopathological and immunohistochemical analyses {#Sec4}
--------------------------------------------------

Histopathological analyses and immunohistochemical evaluation of ER and PgR were performed by the pathological examination group. Tumor specimens obtained by surgery were stored in the refrigerated (4 °C) physiological saline solution for approximately 30 to 90 min and then they were fixed in 20 % buffered formalin solution for 3 to 4 days. Formalin-fixed, paraffin-embedded (FFPE) tissue Sects. (4 µm) were prepared for hematoxylin and eosin (H&E) and hormone receptor IHC stains. Pathological diagnosis and evaluation of histological grade were performed using H&E stained sections. ER and PgR IHC stains were performed by an automated instrument (Autostainer, Dako, Denmark) using primary antibodies for ER (clone 1D5, Dako) and PgR (clone PgR636, Dako). ER and PgR status was determined according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline.

HER2 GPA procedure {#Sec5}
------------------

HER2 GPA performance and analyses were performed by the HER2 GPA exanimation group. HER2 GPA for the simultaneous visualization of HER2 protein, HER2 gene, and chromosome 17 centromere (CEN17) was performed as described before using FFPE tumor tissue Sects. (4 µm) using FDA-approved HER2 IHC and DISH reagents (Ventana Medical Systems, Inc., USA) on an automated staining platform (BenchMark XT, Ventana) \[[@CR7]\]. Briefly, deparaffinized tissue sections were subjected to heat pretreatment and endogenous biotin blocking treatment for HER2 IHC detection. Tissue sections were incubated with anti-HER2 antibody (clone 4B5, Ventana) and the antibody binding site was visualized using a 3,3′ diaminobenzidine IHC kit. After the completion of HER2 IHC staining, HER2 DISH was performed for the detection of HER2 gene and CEN17 targets. HER2 IHC tissue sections were subjected to a second heat pretreatment followed by a protease digestion. A cocktail of 2,4-dinitrophenol (DNP)-labeled HER2 probe and digoxigenin (DIG)-labeled CEN17 probe was hybridized on HER2 IHC stained tissue section. After three stringency wash steps, HER2 and CEN17 probe hybridization sites were visualized using the SISH DNP detection kit and the red ISH DIG detection Kit, respectively. After counterstained with hematoxylin, the slides were cover-slipped for light microscopical observations.

Interpretation of HER2 GPA results {#Sec6}
----------------------------------

Immunohistochemical expression of HER2 protein and status of HER2 gene were simultaneously analyzed in each section according to the package insert of FDA-approved HER2 IHC and DISH assays by a well-experienced pathologist (MP) with both HER2 tests. HER2 IHC staining was scored as followings: score 0 (negative)---no membrane staining is observed; score 1+ (negative)---faint, partial staining of the membrane in any proportion of the cancer cells; score 2+ (equivocal)---weak complete staining of the membrane, greater than 10 % of cancer cells; and score 3+ (positive)---intense complete staining of the membrane, greater than 10 % of cancer cells. HER2 DISH was analyzed by a HER2 to CEN17 signal ratio as followings: HER2/CEN17 \<2.0 (negative) and HER2/CEN17 ≥2.0 (positive). In addition, CEN17 polysomy was defined as an average CEN17 copy number ≥3 per cell.

Evaluation of HER2 discordance and heterogeneity {#Sec7}
------------------------------------------------

Patterns of the HER2 protein and gene status analyzed with the GPA approach were divided into the following six types among individual cases (see Fig. [1](#Fig1){ref-type="fig"}): Type A) IHC & DISH positive; Type B) IHC positive & DISH negative; Type C) IHC equivocal & DISH positive; Type D) IHC equivocal & DISH negative; Type E) IHC negative & DISH positive; and Type F) IHC & DISH negative. Status of HER2 discordance was defined as following two patterns: Type B) IHC positive & DISH negative and E) IHC negative & DISH positive. Cases were categorized HER2 nonheterogeneous when only one type of HER2 protein and gene status combination was observed within one tumor tissue section. On the other hand, cases were categorized HER2 heterogeneous when at least two of the six types of HER2 gene and protein status combinations were observed with individual tumor cells in a tumor tissue section. For example, when a Type F HER2 negative breast case contained individual tumor cells which are not Type F cells, the case is a HER2 heterogeneous case. Before starting this study, the evaluation method of the heterogeneity of HER2 protein expression and HER2 gene status by GPA were confirmed by investigators and the GPA slides of the present study were primarily evaluated by one pathologist (MP) who is one of HER2 GPA induction members.Fig. 1Phenotypic and genotypic human epidermal growth factor receptor 2 (HER2) pattern analyses of breast cancer by the HER2 gene-protein assay method (*n* = 280). *Type A*: HER2 immunohistochemistry (IHC) positive and dual in situ hybridization (DISH) positive (*n* = 44); *Type B*: HER2 IHC positive and DISH negative (*n* = 0); *Type C*: HER2 IHC equivocal and DISH positive (*n* = 11); *Type D*: HER2 IHC equivocal and DISH negative (*n* = 22); *Type E*: HER2 IHC negative and DISH positive (*n* = 5); and *Type F*: HER2 IHC and DISH negative (*n* = 198). *Brown color* indicates HER2 protein expression, *black dots* in the nuclei are HER2 gene, and *red dots* in the nuclei are chromosome 17 centromere

Clinical outcome investigation {#Sec8}
------------------------------

Clinical correlation analyses were conducted by the clinical examination group. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed with HER2 IHC scores among IHC positive, equivocal, and negative populations and HER2 DISH results between DISH positive and negative populations. RFS and CSS were also analyzed between HER2 heterogeneous and nonheterogeneous populations. Because of the size of samples for statistical analyses, patient outcome data were compared between HER2 nonheterogeneous and heterogeneous groups only in Type F (HER2 IHC & DISH negative) patient population.

Statistical analyses {#Sec9}
--------------------

Statistical analyses were performed using SPSS v22.0 (IBM Corp., USA) software. The Kaplan--Meier survival curves and log-rank test were used to estimate RFS and CSS. Chi square and Fisher's exact tests were used to analyze the associations between clinicopathological characteristics and HER2 heterogeneity statues. These factors were included in the univariate and multivariate survival analysis using Cox proportional hazards regression model, and these 95 % confidence interval were assessed for each factor. *P* value \<0.05 were defined statistically significant.

Results {#Sec10}
=======

Clinicopathological characteristics {#Sec11}
-----------------------------------

The clinicopathological characteristics of the 280 cases are summarized in Supplementary File 1. The median age of the patients was 55 years (range, 25--87 years) and the median follow-up duration was 130 months (range, 4 to 149 months) at the time of diagnosis. One hundred nineteen patients (42.5 %) were in pre-menopausal status and 197 (70.4 %) patients had ER positive tumors.

HER2 phenotypic and genotypic analyses {#Sec12}
--------------------------------------

HER2 IHC staining of HER2 GPA showed that 91 cases (32.5 %) were scored 0 (negative), 112 cases (40.0 %) were 1+ (negative), 33 cases (11.8 %) were 2+ (equivocal) and 44 cases (15.7 %) were 3+ (positive). Sixty (21.4 %) tumor specimens were HER2 DISH positive and 220 (78.6 %) were negative (Table [1](#Tab1){ref-type="table"}). Six subtypes of HER2 GPA results were identified among 280 cases as follows (Fig. [1](#Fig1){ref-type="fig"}): (1) Type A (IHC & DISH positive) comprised 44 cases (15.7 %); (2) Type B (IHC positive & DISH negative) comprised no cases (0.0 %); (3) Type C (IHC equivocal & DISH positive) comprised 11 cases (3.9 %); (4) Type D (IHC equivocal & DISH negative) comprised 22 cases (7.9 %); (5) Type E (IHC negative & DISH positive) comprised 5 cases (1.8 %); and 6) Type F (IHC & DISH negative) included 198 cases (70.7 %). Incident of HER2 phenotypic and genotypic discordant was low (0 Type B and 5 Type E cases among 280 cases, 1.8 %) within our cohort (Fig. [2](#Fig2){ref-type="fig"}).Table 1Scores of HER2 IHC and HER2 DISH separately 1 analyzed by GPAHER2 statusNo. of patients%(*n* = 280)HER2 IHC score 09132.5 1+11240.0 2+3311.8 3+4415.7HER2 DISH score Negative22078.6 Positive6021.4*HER2* human epidermal growth factor receptor 2, *IHC* immunohistochemistry, *DISH* dual in situ hybridization, *GPA* gene-protein assayFig. 2Human epidermal growth factor receptor 2 (HER2) intratumoral heterogeneity of HER2 negative breast cancer revealed by the HER2 gene-protein assay. **a** Breast cancer cells showing no HER2 protein expression and nonheterogeneous HER2 gene status. **b** Breast cancer cells showing no HER2 protein expression and heterogeneous HER2 gene status. *Yellow dotted circles* show tumor cells with amplified HER2 gene. *Black dots* and *red dots* in the nuclei are HER2 gene and chromosome 17 centromere, respectively

Survival rate stratified by HER2 protein and gene status {#Sec13}
--------------------------------------------------------

Patients with HER2 IHC 0,1+ (negative) tumors had significantly better survival than those with IHC 3+ (positive) tumors (RFS: HR, = 8.31; *P* = .0039; CSS: HR, 4.39; *P* = .036) (Fig. [3](#Fig3){ref-type="fig"}a, b). RFS of the HER2 IHC 0,1+ group was better than that of the HER2 IHC 2+ (equivocal) group (RFS: HR, 2.93; *P* = .087; CSS: HR, .19; *P* = .66), but survival was not significantly different between the HER2 IHC 2+ (equivocal) group and the HER2 IHC 3+ (positive) group (RFS: HR, .64; *P* = .43; CSS: HR, 1.15; *P* = .28). In addition, patients with HER2 DISH positive tumors had significantly worse survival than those with negative tumors (RFS: HR, 7.67; *P* = .0056; CSS: HR, 3.85; *P* = .050) (Fig. [3](#Fig3){ref-type="fig"}c, d).Fig. 3Survival curves of breast cancer patients (*n* = 280) stratified by the status of human epidermal growth factor receptor 2 (HER2) protein and HER2 gene separately evaluated by the HER2 gene-protein assay. Association of HER2 immunohistochemistry (IHC) scores with **a** recurrence-free survival (RFS) and **b** cancer-specific survival (CSS). Association of HER2 dual in situ hybridization (DISH) status with **c** RFS and **d** CSS

Survival curves stratified by HER2 phenotypic and genotypic types A--F {#Sec14}
----------------------------------------------------------------------

The comparison of survival between each group was shown in Table [2](#Tab2){ref-type="table"} and Supplementary File 2. The HER2 IHC & DISH positive Type A had significantly worse survival than the HER2 IHC & DISH negative Type F (RFS: HR, 4.39; *P* = .0025; CSS: HR, 4.77; *P* = .029). The HER2 IHC negative & DISH positive Type E had significantly worse survival than the HER2 IHC & DISH negative Type F (RFS: HR, 5.34; *P* = .021; CSS: HR, 1.48; *P* = .18). Finally, the HER2 IHC equivocal & DISH negative Type D had significantly worse RFS than the HER2 IHC & DISH negative Type F (RFS: HR, 4.65; *P* = .031; CSS: HR, 0.52; *P* = .47).Table 2Comparison of survival among A--F groups 1 valuated by GPAGroupRecurrence-free survivalCancer-specific survivalACDEACDECHR: 1.18HR: 1.06*P* = 0.28*P* = 0.30DHR: 0.10HR: 0.64HR: 0.51HR: 0.22*P* = 0.75*P* = 0.43*P* = 0.47*P* = 0.64EHR: 0.25HR: 1.40HR: 0.77HR: 0.08HR: 1.26HR: 0.56*P* = 0.61*P* = 0.24*P* = 0.38*P* = 0.78*P* = 0.26*P* = 0.46FHR: 4.39HR: 0.05HR: 4.65HR: 5.34HR: 4.77HR: 0.01HR: 0.52HR: 1.83*P* = 0.0025*P* = 0.82*P* = 0.031*P* = 0.021*P* = 0.029*P* = 0.31*P* = 0.47*P* = 0.18*HR* hazard ratio, *GPA* gene-protein assay

Association of HER2 heterogeneity with the tumor clinicopathological characteristics {#Sec15}
------------------------------------------------------------------------------------

HER2 heterogeneity was recognized in 34 (17.2 %) of 198 HER2 IHC & HER2 DISH negative cases (Type F). As shown in Table [3](#Tab3){ref-type="table"}, the HER2 heterogeneous group contained significantly higher HER2 IHC score 1+ cases (*P* \< .001) than HER2 IHC 0 cases and a higher HER2/CEN17 ratio (*P* = .023) compared to HER2 nonheterogeneous group. Moreover, the presence of HER2 heterogeneity significantly correlated with the presence of chromosome 17 polysomy (*P* = .0011). Other clinicopathologic factors (histological grade, tumor stage, node stage, ER IHC status, and PR IHC status) were not associated with the presence of HER2 heterogeneity.Table 3Relationship between HER2 heterogeneity and clinicopathological characteristics in HER2 IHC 0, 1+ and HER2 DISH negative breast cancerCharacteristicHER2 heterogeneousHER2*P*(*n* = 34)Nonheterogeneous(*n* = 164)Age56 (25--81)55 (26--86).80Tumor stage T1-232144.29 N1-3220Node stage N01690.41 N1-31874Histological grade 1--21690.41 31874HER2 IHC score 1+2879\<.001 0685HER2/CEN17 ratio1.339 (0.798--1.972)1.151 (0.455--1.810).023CEN17 polysomy No30162.0011 Yes42ER IHC score Negative26127.90 Positive837PgR IHC score Negative24111.74 Positive1053TNBC No27132.89 Yes732*HER2* human epidermal growth factor 2, *IHC* immunohistochemistry, *DISH* dual in situ hybridization, *CEN17* chromosome 17 centromere, *ER* estrogen receptor, *PgR* progesterone receptor, *TNBC* triple negative breast cancer

Survival of HER2 IHC & DISH negative patients stratified by presence of HER2 heterogeneity {#Sec16}
------------------------------------------------------------------------------------------

The HER2 heterogeneous group had significantly worse survival than HER2 nonheterogeneous group (RFS: HR, 7.83; *P* = .0051; CSS: HR, 4.92; *P* = .027; Fig. [4](#Fig4){ref-type="fig"}). Multivariate analyses showed that HER2 heterogeneity is one of independent prognostic factors (RFS: *P* = .0076, CSS: *P* = .041, Table [4](#Tab4){ref-type="table"}). Particularly in patients with triple negative breast cancer (TNBC: ER negative, PgR negative and HER2 negative), the HER2 heterogeneous group had significantly worse survival than HER2 nonheterogeneous group (RFS: HR, 13.44; *P* = .00025; CSS: HR, 13.72; *P* = .00021; Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Survival curves of breast cancer patients (*n* = 280) stratified by the presence of human epidermal growth factor receptor 2 (HER2) intratumoral heterogeneity based on the HER2 gene-protein assay analyses. Association of the status of HER2 intratumoral heterogeneity with **a** recurrent-free survival (RFS) and **b** cancer-specific survival (CSS) in Type F (HER2 protein and gene negative) breast cancer (BC) patients. Association of the status of HER2 intratumoral heterogeneity with **c** RFS and **d** CSS in triple negative breast cancer (TNBC) patientsTable 4Results of univariate and multivariate survival-analysis of clinicopathological variable influences including presence of HER2 heterogeneity in HER2 IHC 0, 1+ and HER2 DISH negative breast cancerCharacteristicUnivariate analysisMultivariable analysisRecurrence-free survivalCancer-specific survivalRecurrence-free survivalCancer-specific survivalHR*P*95 % CIHR*P*95 % CIHR*P*95 % CIHR*P*95 % CIAge1.41.370.66--3.011.59.260.71--.3.601.43.380.64--3.211.91.140.81--4.5140\> versus 40≤ Tumor stage2.41.0131.20--4.832.4.0271.11--5.212.29.0381.05--5.022.31.0610.96--5.55 T1-2 versus T3-4Node stage2.75.000851.52--4.992.31.0121.21--4.422.46.00811.26--4.771.95.0740.94--4.05N0 versus N1-3 Histological grade1.18.560.68--2.061.47.220.79--2.750.84.590.44--1.610.85.680.41--1.79 1--2 versus 3CEN17 polysomy2.67.0990.83--8.613.26.051.00--10.622.31.240.57--9.393.48.0770.87--13.89No versus yes ER IHC score1.26.480.67--2.361.73.110.89--3.362.56.210.58--11.193.60.0960.80--16.34 Positive versus negativePgR IHC score1.86.031.06--3.252.35.00711.26--4.363.37.00151.59--7.143.69.00231.59--8.54Positive versus negative TNBC1.2.590.62--2.351.65.160.82--3.300.20.0620.036--1.090.20.0720.04--1.15 No versus yesHER2 heterogeneity2.36.00671.27--4.392.16.0311.07--4.332.65.00761.30--5.402.24.0411.03--4.85No versus yes*HR* hazard ratio, *95% CI* 95% confidence interval, *HER2* human epidermal growth factor 2, *IHC* immunohistochemistry, *DISH* dual in situ hybridization, *CEN17* chromosome 17 centromere, *ER* estrogen receptor, *PgR* progesterone receptor, *TNBC* triple negative breast cancer

Discussion {#Sec17}
==========

It is well established that 15--20 % of breast cancer patients are HER2 positive and it is associated with poor prognosis of breast cancer patients \[[@CR24]\]. After the discovery of HER2 gene, the significance of HER2 gene role was demonstrated by the correlation of overall survival and time to relapse with the HER2 gene amplification in breast cancer \[[@CR24]\]. Additionally, the association of the HER2 gene amplification with the HER2 protein overexpression was proved by immunohistochemical and Western blotting analyses \[[@CR25]\]. In our current research using the HER2 GPA method for detecting both HER2 gene and protein targets, 21.4 % of breast cancer patients (n = 280) were classified as HER2 positive by HER2 gene status and HER2 DISH positive patients had significantly worse survival than HER2 gene negative patients. Also, 15.7 % of breast cancer patients were HER2 IHC positive and HER2 IHC positive patients had significantly worse survival than HER2 IHC negative patients. Consequently, our HER2 GPA study confirmed that HER2 positive breast cancer by either HER2 gene amplification or HER2 protein overexpression demonstrated a poor prognosis. Our cohort consisted with 11.8 % of HER2 IHC 2+ (equivocal) cases that require a reflex test if a traditional single HER2 IHC assay was conducted in a real world. Accurate and prompt HER2 status assessment of HER2 equivocal cases is the major challenge of HER2 testing for improving breast cancer patient care. The ASCO/CAP HER2 testing guideline states that HER2 equivocal breast cancer cases must be reexamined for the HER2 status with a different tissue block, if available, with the same HER2 testing method or by an alternative HER2 testing approach with the same tissue block \[[@CR26]\]. Li et al. \[[@CR27]\] reported that the HER2 GPA approach accurately divided breast cancer cases of a HER2 equivocal enriched cohort to HER2 positive, equivocal, and negative statuses without additional testing. Thus, HER2 GPA method can be utilized effectively for both HER2 positive and equivocal breast cancer cases.

Because HER2 IHC 0, 1+ (negative) cases would not be retested for the HER2 gene status with an ISH assay, if IHC assay was performed first, 1.8 % of patients who were IHC negative & DISH positive with the current cohort would not be eligible for a HER2-targeted therapy. Our statistical analyses showed the HER2 IHC negative & DISH positive group (Type E) had significantly worse survival than the HER2 IHC & DISH negative group (Type F). There are no solid data that if the patient group with HER2 protein negative and gene positive would respond to a HER2-targeted therapy. However, several studies suggested that a subgroup of HER2 negative patients benefit from HER2-targeted therapy \[[@CR15], [@CR16], [@CR28]\]. In the near future, the results of the ongoing NSABP-B47 trial for adjuvant trastuzumab in low HER2 expression breast cancer will be reported and the efficacy of HER2-targeted therapy in low HER2 expression patients will be clarified \[[@CR17]\].

The HER2 gene is localized on q21 of chromosome 17 \[[@CR29]\]. Chromosome 17 polysomy sometimes exists in breast cancer cells \[[@CR30]\] while the majority of CEN17 copy number gains are due to focal pericentromeric gains \[[@CR18]\]. Copy number gain of CEN17 is thought to be a leading reason for discrepancy between HER2 IHC and HER2 ISH status \[[@CR31], [@CR32]\]. It has been suggested that the copy number of CEN17 is important for the accurate assessment of HER2 status \[[@CR31], [@CR33]\]. Even though the definition of CEN17 copy number gain has not been well-defined yet, in general, a mean of \>3 CEN17 signals per nucleus is commonly adopted threshold \[[@CR18]\]. The prevalence rates of CEN17 copy number gain in breast cancer were reported between 3 % and 46 % \[[@CR18], [@CR34]--[@CR49]\]. In our study, approximately 3 % of HER2 IHC & HER2 DISH negative tumors showed CEN17 copy number gain and the presence of CEN17 copy number gain was significantly associated with the presence of HER2 intratumoral heterogeneity. It is suggested that the HER2 intratumoral heterogeneity is caused by the chromosomal instability \[[@CR20]\] and our study also demonstrated that CEN17 copy number gain was significantly correlated with the HER2 heterogeneity. The importance of HER2 gene copy numbers is stated for determining for HER2 status in addition to the ratio of HER2 gene/CEN17 in 2013 ASCO/CAP HER2 \[[@CR26]\]. However, the CEN17 ISH signal copy numbers may still be significant for subtyping breast cancer cases with the HER2 heterogeneity.

Even though the presence of HER2 genetic heterogeneity has been described \[[@CR18], [@CR50]--[@CR52]\], there are no published data on simultaneous phenotypic and genotypic heterogeneity analyses in breast cancer. Hanna et al. \[[@CR18]\] illustrated that HER2 genotypic heterogeneity is categorized into two types: 1) clustered HER2 genotypic heterogeneity and 2) intermixed HER2 genotypic heterogeneity. The clustered heterogeneity type is defined as a cell population of HER2 amplified tumor cells bordered by a HER2 nonamplified tumor cell population. The intermixed genotypic heterogeneity type is defined as comingled HER2 amplified and nonamplified tumor cells within a tumor. In an earlier study, Nitta et al. also reported the findings of two HER2 genotypic heterogeneity types using HER2 DISH assay \[[@CR6]\]. The ASCO/CAP 2013 guidelines state that breast cancer containing between 5 % and 50 % of total cells with HER2/CEN17 ratio \>2.0 or more than 6 HER2 signals per cell should be reported as the HER2 gene amplification heterogeneity \[[@CR50]\]. Allison et al. \[[@CR52]\] reported that HER2 heterogeneity defined by the ASCO/CAP guidelines was present in 23 % of breast cancer. Seol et al. \[[@CR20]\] suggested that HER2 heterogeneity cases are mainly observed among low grade or equivocal HER2 status breast cancer cases. Furthermore, they reported that HER2 intratumoral heterogeneity is associated with short disease-free survival of the patients \[[@CR52]\]. However, our study showed HER2 negative breast cancer cases also showed the HER2 heterogeneity (17 %), although we used a different approach for evaluating the heterogeneity to the ASCO/CAP guidelines. In the present study, initially we evaluated the presence of HER2 heterogeneity only in patients group determined as IHC 0, 1+/DISH negative using FDA criteria as to the routine examination. And then we examined the presence of heterogeneity revealing at least 2 of 6 patterns of HER2-GPA expression such as, (A) IHC 3+/DISH positive; (B) IHC 3+/DISH negative; (C) IHC 2+/DISH positive; (D) IHC 2+/DISH negative; (E) IHC 0, 1+/DISH positive; and (F) IHC 0, 1+/DISH negative, in focal regions less than 10 % area within one tumor. However according to the experts' opinion, HER2 genetic heterogeneity is defined as "more than 5 % but less than 50 % of infiltrating tumor cells with HER2/CEN17 ratio higher than 2.2″ based on HER2 ISH assay results with dual probes \[[@CR51]\]. Because HER2 GPA method allows investigating 6 different HER2 gene and protein combinations at individual cell levels, we anticipate that we will evolve the HER2 tumor heterogeneity definition to another dimension with simultaneous observations of HER2 protein and gene heterogeneity, such as the coexistence of HER2 DISH positive & IHC negative cells with HER2 DISH & IHC positive tumor cells (data not shown). Significance of such the HER2 heterogeneity at the gene and protein levels in breast cancer needs to be investigated for evaluating the efficacy of HER2 targeted therapy with further studies as the therapy target is the protein, not the gene.

Our HER2 GPA data analyses showed that the HER2 heterogeneous group had significantly worse survival than the HER2 nonheterogeneous group among the HER2 IHC & DISH negative breast cancer population. Particularly, TNBC patients with the HER2 intratumoral heterogeneity had significantly worse survival than TNBC patients without the HER2 heterogeneity. TNBC is characterized by ER and PgR IHC staining (\<1 % of positive tumor cells) and HER2 IHC (0 and 1+ scores) or ISH (no gene amplification). TNBC is an aggressive metastatic breast cancer factor like targetable HER2 positive breast cancer, but there are no targeted therapies available for TNBC patients. A systematic review study reported that the 5 year relative survivals of TNBC patients and non-TNBC patients were 77 and 93 %, respectively, among 6370 breast cancer patients \[[@CR53]\]. Unexpectedly, our current HER2 GPA study analyses showed that the HER2 heterogeneity is a significant factor for short patient survival of TNBC and the majority of HER2 heterogeneous TNBC patients died within 5 years. Therefore, we speculate that the HER2 heterogeneity has a significant role for tumor progression in TNBC. In our study, the HER2 heterogeneity of TNBC was defined by having individual tumor cells of non-HER2 IHC & DISH negative in HER2 IHC & DISH negative cell populations. Sweeney et al. reported that 20.3 % TNBC patients were subtyped as HER2-enriched type by PAM50 test for 50 breast cancer classifier gene expression analyses using RT-qPCR \[[@CR54]\]. Intriguingly, our HER2 GPA data analyses showed that 17.9 % of TNBC cases exhibited the HER2 intratumoral heterogeneity. Because breast cancer cases that showed incomplete membrane staining within \>10 % of tumor cells are considered as HER2 negative according to the ASCO/CAP HER2 testing guideline and some HER2 negative breast cancer cases have HER2 IHC staining, it is not a surprising observation to detect the expression of HER2 mRNA with TNBC. Thus, it might be possible that amplified HER2 gene tumor cells without obvious HER2 protein expression start overexpressing the HER2 protein later in the cancer progression of TNBC. A combination of HER2 mRNA and DNA ISH assays on the same tissue sections allows further analyses of HER2 gene expression at individual cell levels in TNBC. To our knowledge we are the first team to report that the HER2 intratumoral heterogeneity might be a poor prognosis factor in TNBC patients. If this is a true breast cancer biological phenomenon, we might be able to develop a new therapy strategy for TNBC patients comparing between HER2 heterogeneous and nonheterogeneous patient groups. It might be a reasonable approach to treat HER2 heterogeneous TNBC patients with HER2-targeted therapy. Further studies are commanded to confirm our observations with TNBC patients and investigate opportunity to develop a new therapy approach for TNBC with the heterogeneity.

Conclusions {#Sec18}
===========

We demonstrated that the HER GPA approach, which allows the simultaneous evaluation of HER 2 gene and protein at individual cell levels, is useful for more accurate HER2 status assessment, particularly with HER2 IHC negative & DISH positive cases (HER2 IHC & DISH discordant cases) and the HER2 intratumoral heterogeneity evaluation. Our study suggested that the HER2 intratumoral heterogeneity detected with the GPA is a poor prognostic factor among HER2 negative breast cancer cases, especially with TNBC. Our study also advocates that an improvement of HER2 testing methods are required for comprehensive analyses of the HER2 gene and protein discrepancy and the HER2 intratumoral heterogeneity comparing to clinical outcome data for the refinement of breast cancer patient selections for targeted therapies. However, since the examination criteria for the HER2 discrepancy and intratumoral heterogeneity have not been standardized yet, further studies are required for the establishment of HER2 GPA scoring algorithm.
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ADCC

:   Antibody-dependent cell-medicated cytotoxicity

ASCO/CAP

:   The American Society of Clinical Oncology and College of American Pathologists

CISH

:   Chromogenic in situ hybridization

CEN17

:   Chromosome 17 centromere

CSS

:   Cancer-specific survival

DAB

:   3,3′-Diamnobenzidine

DIG

:   Digoxigenin

DISH

:   Dual in situ hybridization

DNP

:   2,4′-Dinitrophenol

EGFR

:   Epidermal growth factor

ER

:   Estrogen receptor

FDA

:   U.S. Food and Drug Administration

FFPE

:   Formalin-fixed, paraffin-embedded

FISH

:   Fluorescent in situ hybridization

GPA

:   Gene-protein assay

H&E

:   Hematoxylin and eosin

HER2

:   Human epidermal growth factor receptor 2

HR

:   Hazard ratio

IHC

:   Immunohistochemistry

NSABP

:   National Surgical Adjuvant Breast and Bowel Project

PAM50

:   Prosigna Breast Cancer Prognostic Gene Signature Assay

PR

:   Progesterone receptor

RFS

:   Recurrence-free survival

ISH

:   In situ hybridization

RT-qPCR

:   Reverse transcription quantitative polymerase chain reaction

SISH

:   Silver in situ hybridization

T-DM1

:   Ado-trastuzumab emtansine

TNBC

:   Triple negative breast cancer
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